ReShape Lifesciences Valuation
| RSLS Stock | USD 3.18 0.33 11.58% |
At this time, the company appears to be overvalued. ReShape Lifesciences holds a recent Real Value of $2.03 per share. The prevailing price of the company is $3.18. Our model determines the value of ReShape Lifesciences from analyzing the company fundamentals such as Return On Equity of -1.2, operating margin of (1.65) %, and Return On Asset of -0.53 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ReShape Lifesciences' valuation include:
Overvalued
Today
Please note that ReShape Lifesciences' price fluctuation is abnormally volatile at this time. Calculation of the real value of ReShape Lifesciences is based on 3 months time horizon. Increasing ReShape Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ReShape stock is determined by what a typical buyer is willing to pay for full or partial control of ReShape Lifesciences. Since ReShape Lifesciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ReShape Stock. However, ReShape Lifesciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.18 | Real 2.03 | Target 1.0 | Hype 3.62 | Naive 3.6 |
The intrinsic value of ReShape Lifesciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ReShape Lifesciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ReShape Lifesciences helps investors to forecast how ReShape stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ReShape Lifesciences more accurately as focusing exclusively on ReShape Lifesciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ReShape Lifesciences' intrinsic value based on its ongoing forecasts of ReShape Lifesciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ReShape Lifesciences' closest peers.
ReShape Lifesciences Cash |
|
ReShape Valuation Trend
ReShape Lifesciences' real value is important for investors to make better decisions and a more accurate overall view of ReShape Lifesciences' financial worth over time. Using both ReShape Lifesciences' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
ReShape Revenue by Product
ReShape Lifesciences Total Value Analysis
ReShape Lifesciences is at this time expected to have valuation of 4.01 M with market capitalization of 7.59 M, debt of 967 K, and cash on hands of 11.49 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ReShape Lifesciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.01 M | 7.59 M | 967 K | 11.49 M |
ReShape Lifesciences Investor Information
The company recorded earning per share (EPS) of 264.12. ReShape Lifesciences last dividend was issued on the 25th of July 2019. The entity had 1:25 split on the 9th of May 2025. Based on the key indicators related to ReShape Lifesciences' liquidity, profitability, solvency, and operating efficiency, ReShape Lifesciences may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.ReShape Lifesciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ReShape Lifesciences has an asset utilization ratio of 167.04 percent. This implies that the Company is making $1.67 for each dollar of assets. An increasing asset utilization means that ReShape Lifesciences is more efficient with each dollar of assets it utilizes for everyday operations.ReShape Lifesciences Ownership Allocation
ReShape Lifesciences holds 10.62 pct. of its outstanding shares held by insiders and 0.72 pct. owned by third-party entities.ReShape Lifesciences Profitability Analysis
The company reported the previous year's revenue of 8.01 M. Net Loss for the year was (7.13 M) with profit before overhead, payroll, taxes, and interest of 4.57 M.About ReShape Lifesciences Valuation
The stock valuation mechanism determines ReShape Lifesciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of ReShape Lifesciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ReShape Lifesciences. We calculate exposure to ReShape Lifesciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ReShape Lifesciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 5.1 M | 3.4 M | |
| Pretax Profit Margin | (0.89) | (0.93) | |
| Operating Profit Margin | (0.83) | (0.87) | |
| Net Loss | (0.89) | (0.94) | |
| Gross Profit Margin | 0.63 | 0.43 |
ReShape Lifesciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as ReShape Lifesciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 515.6 K |
ReShape Lifesciences Current Valuation Indicators
ReShape Lifesciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ReShape Lifesciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ReShape Lifesciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ReShape Lifesciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ReShape Lifesciences' worth.Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.